Literature DB >> 11929335

Treatment of sexually transmitted infections with single-dose therapy: a double-edged sword.

Margaret Kingston1, Elizabeth Carlin.   

Abstract

Since the advent of the antimicrobial era, single-dose therapy has been a valuable tool in the management of genital infection. Most of the common sexually transmitted infections (STIs) such as gonorrhoea, syphilis, trichomoniasis and chancroid can be treated in this way, as can genital infections which are not sexually transmitted such as bacterial vaginosis and genital tract candidiasis. Until recently, treatment for Chlamydia trachomatis infection required a multi-dose regimen, but single-dose azithromycin has now been shown to be an effective and acceptable alternative to this. Unfortunately, eradicative therapy has proven to be elusive for the viral STIs such as genital herpes simplex infection, human papilloma virus infection and human immunodeficiency virus (HIV) infection. The main advantage of single-dose therapy lies in its convenience and in its ability to ensure virtually 100% compliance. This addresses the problems of reduced clinical efficacy and the difficulties in assessing the response to therapy which complicates poor treatment compliance. However, some single-dose regimens for STIs do have drawbacks, particularly in certain situations. This may be with respect to efficacy, for example in syphilis with single-dose benzathine penicillin therapy, particularly for pregnant women and individuals infected with HI. Alternatively, it may involve toxicity, for example with single-dose metronidazole therapy for trichomoniasis or bacterial vaginosis where a higher rate of gastrointestinal adverse effects may be expected than if a lower multi-dose regimen is used. In addition, single-dose therapy, for example with nevirapine, given to the mother in labour and to the baby after delivery significantly reduces the risk of mother to child HIV transmission, but resistance mutations are frequently detected in the viral genome after the brief exposure to the drug, which could jeopardise its future use. Single-dose therapy clearly has both advantages and disadvantages. We have reviewed a range of these in a variety of situations, focussing on their applications, effectiveness, compliance and toxicity, highlighting how single-dose therapy may be a double-edged sword.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11929335     DOI: 10.2165/00003495-200262060-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  42 in total

1.  National guideline for the management of Trichomonas vaginalis. Clinical Effectiveness Group (Association for Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases).

Authors: 
Journal:  Sex Transm Infect       Date:  1999-08       Impact factor: 3.519

2.  Compliance with tricyclic antidepressants: the value of four different methods of assessment.

Authors:  C F George; R C Peveler; S Heiliger; C Thompson
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

3.  Asthma drug adherence in a long term clinical trial.

Authors:  G Jónasson; K H Carlsen; P Mowinckel
Journal:  Arch Dis Child       Date:  2000-10       Impact factor: 3.791

4.  How often is medication taken as prescribed? A novel assessment technique.

Authors:  J A Cramer; R H Mattson; M L Prevey; R D Scheyer; V L Ouellette
Journal:  JAMA       Date:  1989-06-09       Impact factor: 56.272

5.  Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes: high therapeutic success rates despite poor compliance.

Authors:  L H Bachmann; J Stephens; C M Richey; E W Hook
Journal:  Sex Transm Dis       Date:  1999-05       Impact factor: 2.830

6.  A randomized, double-blind, placebo-controlled trial of single-dose ciprofloxacin versus erythromycin for the treatment of chancroid in Nairobi, Kenya.

Authors:  I M Malonza; M W Tyndall; J O Ndinya-Achola; I Maclean; S Omar; K S MacDonald; J Perriens; K Orle; F A Plummer; A R Ronald; S Moses
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

7.  Treatment of male partners and recurrence of bacterial vaginosis: a randomised trial.

Authors:  E Colli; M Landoni; F Parazzini
Journal:  Genitourin Med       Date:  1997-08

8.  Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women. A use-effectiveness study in public health settings.

Authors:  S D Hillis; F B Coles; B Litchfield; C M Black; B Mojica; K Schmitt; M E St Louis
Journal:  Sex Transm Dis       Date:  1998-01       Impact factor: 2.830

9.  Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men.

Authors:  D W Cameron; J N Simonsen; L J D'Costa; A R Ronald; G M Maitha; M N Gakinya; M Cheang; J O Ndinya-Achola; P Piot; R C Brunham
Journal:  Lancet       Date:  1989-08-19       Impact factor: 79.321

10.  Single-dose azithromycin for Chlamydia in pregnant women.

Authors:  H A Wehbeh; R M Ruggeirio; S Shahem; G Lopez; Y Ali
Journal:  J Reprod Med       Date:  1998-06       Impact factor: 0.142

View more
  4 in total

1.  [Therapy of syphilis].

Authors:  M Hartmann
Journal:  Hautarzt       Date:  2004-02       Impact factor: 0.751

2.  Chlamydia and gonorrhoea in pregnancy: effectiveness of diagnosis and treatment in Botswana.

Authors:  M Romoren; M Rahman; J Sundby; P Hjortdahl
Journal:  Sex Transm Infect       Date:  2004-10       Impact factor: 3.519

3.  Chlamydia Treatment Practices and Time to Treatment in Massachusetts: Directly Observed Therapy Versus Pharmacy Prescriptions.

Authors:  Laura Platt; Heather Elder; Ingrid V Bassett; Lauren Molotnikov; Monina Klevens; Erin O'Connor; Dylan Leach; Kathleen Roosevelt; Katherine Hsu
Journal:  J Prim Care Community Health       Date:  2021 Jan-Dec

4.  High Resistance to Azithromycin in Clinical Samples from Patients with Sexually Transmitted Diseases in Guangxi Zhuang Autonomous Region, China.

Authors:  Bangyong Zhu; Jin Bu; Wei Li; Jie Zhang; Geng Huang; Juan Cao; Zhongshu Tang; Quan Gan; Pingjiang Wei
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.